The Graves’ orbitopathy treatment market was worth $2.1 billion in 2024 across leading regions, with the USA accounting for 96% of sales, according to a new DelveInsight report.

US late-stage biotech Rocket Pharmaceuticals today announced via a Securities Exchange filing that it has voluntarily withdrawn its Biologics License Application (BLA) to the US Food and Drug ...

Following its October management board meeting, the European Medicines Agency (EMA) has presented results and achievements of its operations for the first half of 2025.

San Diego, USA-based biotech Cidara Therapeutics yesterday revealed it has received an award valued up to $339 million from the Biomedical Advanced Research and Development Authority (BARDA), part of ...

US clinical-stage biotech OncoC4 revealed it has closed a Series B financing round of nearly $50 million, led by GBA Fund, and supported by additional capital from the company's co-founders and ...

US biotech Cirrus Therapeutics has emerged from stealth with $11 million in seed financing to advance a gene therapy for dry age-related macular degeneration (AMD). The round, led by Singapore’s ...

Ireland-based Jazz Pharmaceuticals has announced the US Food and Drug Administration (FDA) approval of Zepzelca (lurbinectedin) alongside Roche’s (ROG: SIX) Tecentriq (atezolizumab) or atezolizumab ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to NPI-001 (N-acetylcysteine amide) tablets, Texas, USA-based clinical-stage biotech Nacuity ...

India’s pharmaceutical industry has long been cast as the world’s pharmacy, churning out affordable generics and APIs at industrial scale. That narrative still holds, but a new one is taking shape: ...

US biotech Amgen (Nasdaq: AMGN) has reported that its cholesterol therapy Repatha (evolocumab) hit both primary endpoints in the Phase III Vesalius-CV trial, reducing the risk of major adverse ...

Following regulatory approval earlier this year, South Korean firm Celltrion’ Avtozma (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the USA.

Japan’s largest drugmaker Takeda today revealed that, as part of a strategic portfolio prioritization process, it has made the decision to discontinue its cell therapy efforts.